文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

如何个体化选择JAK抑制剂治疗骨髓纤维化患者

How I individualize selection of JAK inhibitors for patients with myelofibrosis.
PubMed 文献 · Blood · 2025-01-01

该文综述了美国已批准用于中危或高危骨髓纤维化的四种JAK抑制剂(芦可替尼、非德拉替尼、帕克替尼、莫美替尼)的临床试验与治疗特性,提出应根据患者主要临床表现及血细胞减少类型/程度(骨髓增殖型/血细胞减少型)个体化选择并排序JAK抑制剂,并通过3个临床案例展示临床实践方法。

要点

  • 芦可替尼和非德拉替尼可致骨髓抑制,推荐用于骨髓增殖型患者。
  • 帕克替尼和莫美替尼骨髓抑制较轻,分别为严重血小板减少和贫血患者提供选择。
  • 莫美替尼可使严重贫血患者达到输血独立,且输血独立与总生存延长相关。

核心结论

  • 对JAK抑制剂关键临床试验及其治疗特性的深入理解有助于做出明智的治疗决策,并应以主要临床表现和血细胞减少类型/程度(骨髓增殖型/血细胞减少型)为指导。

研究设计与样本

  • 本文为综述,通过3个临床案例展示作者对骨髓纤维化患者使用JAK抑制剂及其排序的临床方法。

主要发现

  • 美国已批准四种JAK抑制剂用于中危或高危骨髓纤维化。
  • 首个JAK1/2抑制剂芦可替尼于2011年获批,显著控制脾肿大和体质性症状、改善生活质量并延长生存。
  • 非德拉替尼是第二个获批的JAK抑制剂,优选用于二线治疗。
  • 芦可替尼和非德拉替尼可致骨髓抑制,推荐用于骨髓增殖型患者。
  • 帕克替尼和莫美替尼骨髓抑制较轻,分别为严重血小板减少和贫血患者提供必要治疗选择;莫美替尼和帕克替尼是强效activin A受体1型抑制剂,对贫血患者有显著获益;莫美替尼使严重贫血患者达到输血独立,且输血独立与总生存延长相关。

临床怎么用

  • 作者根据主要临床表现和血细胞减少类型/程度(骨髓增殖型/血细胞减少型)个体化选择JAK抑制剂并进行排序。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advent of Janus kinase inhibitors (JAKis) inaugurated a novel era in the treatment of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical manifestations. Four JAKis have been approved for intermediate or high-risk MF, in the United States. Regulatory approval of the first JAK1/2 inhibitor, ruxolitinib, in 2011, transformed the landscape of MF by markedly controlling splenomegaly and constitutional symptoms, improving patients' quality of life, and prolonging survival. Fedratinib, the second approved JAKi, is preferred in the second-line setting. Ruxolitinib and fedratinib can cause myelosuppression and are recommended for patients with the myeloproliferative phenotype. The approval of 2 less-myelosuppressive JAKis, pacritinib and momelotinib, provided essential treatment options for patients with severe thrombocytopenia and anemia, respectively. Momelotinib and pacritinib are potent activin A receptor, type 1 inhibitors with consequent significant benefits for patients with anemia. Transfusion independence was achieved with momelotinib in patients who were severely anemic, and the association of transfusion independence with prolonged overall survival was demonstrated. Judicious treatment decisions regarding JAKis can be made with in-depth understanding of the pivotal clinical trials that evaluated JAKis and their therapeutic attributes and should be guided by the dominant clinical manifestations and the type/degree of cytopenia(s) (myeloproliferative/cytopenic phenotypes). This article reviews our clinical approach to treatment with JAKis and their sequencing in patients with MF by presenting 3 clinical vignettes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Masarova L, Chifotides HT. How I individualize selection of JAK inhibitors for patients with myelofibrosis. Blood. 2025. PMID: 39357058. doi:10.1182/blood.2023022415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。